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Edited by Sandro SonninoAbstract Sphingosine-1-phosphate (S1P) is a potent lysolipid
involved in a variety of biological responses important for cancer
progression. Therefore, we investigated the role of sphingosine
kinase type 1 (SphK1), the enzyme that makes S1P, in the motil-
ity, growth, and chemoresistance of MCF-7 breast cancer cells.
Epidermal growth factor (EGF), an important growth factor for
breast cancer progression, activated and translocated SphK1 to
plasma membrane. SphK1 was required for EGF-directed motil-
ity. Downregulation of SphK1 in MCF-7 cells reduced EGF- and
serum-stimulated growth and enhanced sensitivity to doxorubi-
cin, a potent chemotherapeutic agent. These results suggest that
SphK1 may be critical for growth, metastasis and chemoresis-
tance of human breast cancers.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Sphingosine-1-phosphate (S1P) is a potent bioactive lipid
that is produced by two sphingosine kinase (SphK) isoen-
zymes, SphK1 and SphK2. S1P is a ligand for a family of ﬁve
cell surface G protein-coupled receptors (S1PRs), termed
S1P1–5, and this has endowed S1P with the ability to regulate
a plethora of cellular functions important for cancer, including
growth, survival, cytoskeletal rearrangements and locomotion
[1–3]. S1P also has eﬀects that are independent of its cell sur-
face receptors, notably those on cell growth and survival [4],
although it has proved diﬃcult to identify its direct intracellu-
lar targets. A large number of stimuli, including cytokines and
growth factors, as well as crosslinking of the high aﬃnity IgEAbbreviations: EGF, epidermal growth factor; EGFR, epidermal
growth factor receptor; PM, plasma membrane; QPCR, quantitative
real-time polymerase chain reaction; si, small interfering; siControl,
small interfering control RNA; siSphK1, small interfering RNA
against SphK1; S1P, sphingosine-1-phosphate; S1PR, S1P receptor;
SphK1, sphingosine kinase type 1
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doi:10.1016/j.febslet.2005.08.055receptor, stimulate SphK1 and formation of S1P (reviewed in
[1]), which in turn, by autocrine or paracrine mechanisms, acti-
vates S1PRs and their downstream signaling. This type of ‘‘in-
side-out’’ transactivation has been shown to be important for
migration of cells towards PDGF [5,6] and for mast cell func-
tions, such as degranulation and motility towards antigen [7].
Epidermal growth factor (EGF) plays a critical role in pro-
gression, invasion, and tumorigenicity of human breast cancers.
Expression of epidermal growth factor receptor (EGFR) in
breast cancer is associated with poor prognosis and reduced
responsiveness to anti-hormone therapy [8] and this has made
EGFR an attractive target for clinical treatment [9]. Similar to
EGF, ectopic SphK1 expression increases tumorigenicity and
angiogenesis [10,11]. Overexpression of SphK1 also protects
breast cancer cells from apoptosis [10]. EGF has been
reported to stimulate SphK in HEK 293 cells [12] and to induce
cell migration via transactivation of S1PRs [13]. Conversely,
exogenous S1P can transactivate the EGFR [14], which is
required for S1P-induced activation of ERK1/2. Here, we exam-
ined the functions of endogenous SphK1 in motility, growth,
and chemoresistance of MCF-7 human breast cancer cells.2. Materials and methods
2.1. Materials
All lipids were obtained from Biomol (Plymouth Meeting,
PA). Serum and medium were from Bioﬂuids (Rockville,
MD). [c-32P] ATP (3000 Ci/mmol) was purchased from Amer-
sham Pharmacia Biotech (Piscataway, NJ). EGF was from
Life Technologies (Gaithersburg, MD). Rabbit polyclonal
antibody against SphK1 was made as described [15]. Anti-
caspase-7 and anti-PARP antibodies were obtained from Cell
Signaling Technology (Beverly, MA) and anti-b-tubulin
antibodies were from Santa Cruz (Santa Cruz, CA).
2.2. Cell culture, transfection, and mRNA analysis
MCF-7 cells were maintained in IMEM without phenol red
supplemented with 10% FBS. Cells were transfected using
Lipofectamine Plus (Invitrogen). SphK1 constructs have been
described previously [16,17]. Where indicated, stable pooled
transfectants were selected with 1 mg/ml G418. MCF-7 cells
were transfected with 200 nM control siRNA and siRNA
against SphK1 (sequence targeted: GGGCAAGGCCTTG-
CAGCTC, obtained from Qiagen (Valencia, CA)) [15], usingblished by Elsevier B.V. All rights reserved.
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tive PCR (QPCR) was performed as described [15] with pre-
mixed primer-probe sets obtained from Applied Biosystems
Inc. (Foster City, CA).
2.3. Fractionation, SphK activity, and Western blotting
Cells were lysed by freeze-thawing in SphK assay buﬀer
(20 mM Tris (pH 7.4), 20% glycerol, 1 mM 2-mercaptoethanol,
1 mM EDTA, 5 mM sodium orthovanadate, 40 mM b-glycer-
ophosphate, 15 mM NaF, 0.5 mM 4-deoxypyridoxine, and
Sigma protease inhibitor cocktail). Unbroken cells were re-
moved by centrifugation at 700 · g for 10 min. SphK1 activity
measured in 100000 · gmembrane fractions was determined in
the presence of 5 or 50 lM sphingosine and 0.25% Triton
X-100 essentially as described [18,19]. Speciﬁc activity is
expressed as pmol S1P formed per min per mg protein. Down-
regulation of SphK1 protein was conﬁrmed by Western blot-
ting using SphK1-speciﬁc antibody as described [15].
2.4. Immunocytochemistry and confocal microscopy
Transfectants were grown on glass slides, washed with PBS,
ﬁxed for 20 min at room temperature with 3% paraformalde-
hyde, permeabilized with 0.1% Triton X-100 in PBS for
10 min, and blocked for 10 min in phosphate-buﬀered saline
containing 1% bovine serum albumin. After washing, cells
were incubated for 60 min with anti-SphK1 antibody in PBS
containing 0.1% BSA, and then for 60 min with FITC-conju-
gated anti-rabbit secondary antibody (Jackson ImmunoRe-
search, West Grove, PA). Coverslips were mounted on glass
slides and images collected on an LSM 510 laser confocal
microscope (Zeiss, Thornwood, NY) with a 63X oil immersion
objective as described [20].
2.5. Cell migration assay
Chemotaxis was measured in a modiﬁed Boyden chamber
using polycarbonate ﬁlters (25 · 80 mm, 12 lm pores, NeuroP-
robe Inc., Gaithersburg, MD) coated with human collagen
type IV (10 lg/ml in 0.05 M HCl, Collagen Corp., Palo Alto,
CA) as described [21].Fig. 1. EGF activates and translocates SphK1 to the plasma membrane. (A) M
24 h, serum-starved overnight and treated without or with EGF (100 ng/ml)
confocal microscopy. Arrows indicate lamellipodia. (B,C) MCF-7 cells transie
the indicated times, lysed, and membrane fractions prepared by centrifu
sphingosine added in 0.25% Triton X-100. Data are means ± S.E. of three ind
of proteins from membrane fractions were separated by SDS–PAGE and
reprobed with anti-protein disulﬁde isomerase (PDI) antibodies as loading co
starved over night, then allowed to migrate for 24 h towards vehicle (None
modiﬁed Boyden chamber. Data are expressed as average number of cells p2.5. Cell cycle and proliferation assays
Analyses of cell cycle proﬁles by ﬂow cytometry were carried
out as described [17]. Brieﬂy, cells were trypsinized, washed,
ﬁxed, and stained with propidium iodide (0.05 mg/ml in
3.8 lM sodium citrate, 0.1% Triton X-100, and 7 kU/ml RNa-
seB) for 2 h and separated on a Beckman–Coulter XL-MCL
ﬂow cytometer (Hialeah, FL). The data were analyzed using
Mod Fit LT 3.0 (Verity Software House; Topsham, ME). Cell
growth was also measured by adding WST-1 reagent (Roche,
Indianapolis, IN) and incubating at 37 C for 1 h. Absorbance
was measured at 450 nm with background subtraction at
630 nm.
2.6. Cell death assays
Cells were ﬁxed by addition of an equal volume of PBS con-
taining 4% paraformaldehyde and 4% sucrose, and apoptosis
was assessed by staining with 8 lg/ml Hoechst 33342. Cleavage
of caspase-7 and PARP were determined with antibodies that
recognize cleavage fragments [22].3. Results and discussion
3.1. EGF induced translocation and activation of SphK1 at the
plasma membrane of MCF-7 cells
Sphingosine, the substrate for SphK1, is a membrane-associ-
ated sphingolipid metabolite. SphK1 is translocated to the
plasma membrane (PM) upon treatment of cells with a variety
of agonists, including PDGF [23], and this localization is re-
quired for its stimulatory eﬀects on proliferation, survival,
and transformation of NIH 3T3 cells [24]. Given the important
role of EGF in progression, invasion, and tumorigenicity of
human breast cancers [8], we examined whether EGF induced
translocation of SphK1 to the PM of estrogen-dependent
MCF-7 human breast cancer cells. In agreement with many
other reports [25], confocal microscopy revealed that SphK1
had a diﬀuse, cytosolic staining in unstimulated cells indicative
of cytosolic localization (Fig. 1A). However, upon addition of
EGF, SphK1 rapidly translocated to the PM, in particular toCF-7 cells were transfected with SphK1, grown on glass coverslips for
for 5 min. SphK1 was immunoﬂuorescently stained and visualized by
ntly transfected with SphK1 were stimulated with EGF (100 ng/ml) for
gation at 100000 · g. (B) SphK1 activity was measured with 5 lM
ependent experiments, each performed in duplicate. (C) Equal amounts
immunoblotted with anti-SphK1 antibody. Blots were stripped and
ntrols. (D) MCF7 cells transfected with vector or SphK1 were serum-
), EGF (100 ng/ml), S1P (100 nM), or ﬁbronectin (FN, 20 lg/ml) in a
er ﬁeld ± S.D. of triplicate determinations.
Fig. 3. SphK1 is required for EGF-induced migration and prolifer-
ation. (A) MCF-7 cells were transfected with control siRNA (open
bars) or siRNA targeted to SphK1 (ﬁlled bars), serum-starved
overnight, then allowed to migrate for 6 h towards medium (None),
EGF (100 ng/ml), S1P (100 nM), or ﬁbronectin (FN, 20 lg/ml) in a
modiﬁed Boyden chamber. Data are expressed as mean number of cells
per ﬁeld ± S.D. of triplicate determinations. (B) MCF-7 cells transfec-
ted with control siRNA (open symbols) or siSphK1 (ﬁlled symbols)
were cultured in serum-free medium supplemented with EGF (100 ng/
ml) and cell proliferation determined with WST-1 at the indicated
times. (C) MCF-7 cells transfected with control siRNA or siSphK1
were cultured in the absence or presence of EGF (100 ng/ml). After
48 h, cellular DNA was stained with propidium iodide and cell cycle
analysis was performed with a ﬂow cytoﬂuorometer. Data are
means ± S.D. of percent cells in each cell cycle phase.
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SphK1 antibody conﬁrmed that SphK1 is translocated to
membranes within 1 min after EGF treatment (Fig. 1C) with
a concomitant increase in SphK1 activity in membrane frac-
tions (Fig. 1B). These results indicate that EGF, like other
growth factors, induces translocation of SphK1 to the PM,
increasing phosphorylation of sphingosine there, and suggest
that formation of S1P by SphK1 plays a role in mediating
the eﬀects of EGF.
3.2. SphK1 is involved in EGF-induced cell migration
Because EGF induced SphK1 translocation to lamellipodia,
PM structures that are typically involved in cell motility
(Fig. 1A), we next examined the role of SphK1 in migration to-
wards EGF. In agreement with other studies [8], EGF induced
migration of MCF-7 cells (Fig. 1D). Expression of SphK1 sig-
niﬁcantly enhanced migratory responses towards EGF. How-
ever, SphK1 did not aﬀect migration towards ﬁbronectin,
ruling out general eﬀects on cell motility. Intriguingly, expres-
sion of SphK1 decreased migration towards S1P, its product,
while having little eﬀect on migration towards vehicle. This
observation is reminiscent of the eﬀect of SphK1 overexpres-
sion on migration of RBL-2H3 mast cells [7], and is likely
due to the desensitization of S1P receptors.
Collectively, these results suggest that SphK1 may be a
downstream eﬀector of EGF-induced motility of MCF-7
human breast cancer cells. To further investigate this notion,
endogenous SphK1 expression was downregulated by siRNA
targeted to a speciﬁc SphK1 sequence. As expected, this
siRNA speciﬁcally knocked-down SphK1 mRNA without
changing the level of SphK2 mRNA (Fig. 2A). Small interfer-
ing RNA against SphK1 (siSphK1) also reduced SphK1 activ-
ity (Fig. 2B) and protein levels (Fig. 2C). However, it should be
noted that even though western blots indicate nearly complete
loss of SphK1 protein, some residual SphK1 activity measured
in the presence of Triton X-100 could still be detected. Impor-
tantly, downregulation of SphK1 completely blocked migra-
tion of MCF-7 cells towards EGF (Fig. 3A). In contrast,
transfection with control siRNA had no signiﬁcant eﬀect on
motility towards EGF (Fig. 3A). Interestingly, while naı¨ve cells
or small interfering control RNA (siControl) treated cells didFig. 2. Downregulation of SphK1 with siRNA. (A) MCF7 cells were transfec
bars). RNA was isolated and mRNA levels of SphK1 and SphK2, and 18 S R
transfected with siControl or siSphK1 were lysed and membrane and cytosol
measured in the presence of 50 lM sphingosine added as mixed micelles w
100000 · g supernatants were immunoblotted with anti-SphK1. Lysates fro
were stripped and reprobed with anti-b-tubulin to conﬁrm equal loading.not signiﬁcantly migrate towards S1P, downregulation of
SphK1 with siRNA increased migration towards S1P. These
results are consistent with the eﬀects of overexpression, indi-
cating that SphK1 plays a role in EGF-induced cell migration.
3.3. Role of SphK1 in proliferation and apoptosis of MCF-7 cells
Because EGF is a well-established growth factor for MCF-7
cells [8], we also examined the eﬀect of downregulating SphK1
expression on EGF-induced proliferation. Decreasing SphK1
levels markedly reduced the cell growth response to EGF
(Fig. 3B). As expected cell cycle analysis revealed that EGF in-
creased the fraction of MCF-7 cells in the S phase of the cellted with control siRNA (open bars) or siRNA targeted to SphK1 (ﬁlled
NA were determined by quantitative real-time PCR. (B) MCF-7 cells
fractions prepared by centrifugation at 100000 · g. SphK1 activity was
ith 0.25% Triton X-100. (C) Equal amounts of proteins (40 lg) from
m untransfected MCF-7 cells (mock) were included as controls. Blots
Fig. 4. Downregulation of SphK1 suppresses cell growth and enhances sensitivity to doxorubicin. (A) MCF-7 cells transfected with control siRNA
(open symbols) or siSphK1 (ﬁlled symbols) were cultured in medium containing 5% serum and cell proliferation determined with WST-1 at the
indicated times. (B) MCF-7 cells transfected with control siRNA or siSphK1 were cultured in the presence of medium containing 10% serum for 48 h,
and cell cycle analyzed by FACS. (C) MCF-7 cells transfected with siControl (open bars) or siSphK1 (ﬁlled bars) were cultured in medium containing
10% serum in the absence () or presence (+) of doxorubicin (1 lg/ml) for 24 and 48 h, and apoptosis determined. (D) Duplicate cultures were lysed
24 h after treatment with doxorubicin and equal amounts of proteins resolved by SDS–PAGE, blotted, and probed with anti-caspase-7, anti-PARP
antibodies, or anti-tubulin for loading control. Arrows indicate active subunit p20 of caspase-7 and p116 full length PARP and its p89 fragment.
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reduction of SphK1 reduced the progression of the cells into
S and G2/M phases of the cell cycle, even in the presence of
EGF, with a corresponding increase in cells arresting in G0/
G1 (Fig. 3C).
Overexpression of SphK1 in various cell types including
MCF-7 cells has been shown to promote cell growth, enhance
the G1/S transition and to increase cells in S-phase [10,17]. In-
deed, downregulation of SphK1 in MCF-7 cells with siSphK1
even reduced their growth when cultured in the presence of ser-
um (Fig. 4A). In agreement, in the presence of serum, which
markedly increased the proportion of cells in the S phase
and G2/M phase, siSphK1, but not control siRNA, reduced
the percentage of cells in S and G2/M phases while increasing
the percentage of cells in G0/G1 phase (Fig. 4B). Together,
these results suggest that basal SphK1 activity regulates the
progression of MCF-7 cells through the cell cycle.
In numerous studies, expression of SphK1 has also been
linked to protection of cells from apoptosis [25]. Overexpres-
sion of SphK1 inhibits apoptosis of MCF-7 cells [10], and
induction of apoptosis in these cells leads to the degradation
of SphK1 [26]. Because resistance to anti-cancer drugs is a
common feature in breast cancer therapy and sensitivity to
doxorubicin is potentiated pharmacologically with dimethylsp-
hingosine [10], a pan SphK inhibitor, it was of interest to
examine whether the loss of SphK1 increased susceptibility
of MCF-7 cells to apoptosis induced by doxorubicin, one of
the most active antineoplastic agents used clinically. siSphK1
markedly enhanced apoptosis of MCF-7 cells induced by
doxorubicin (Fig. 4C).
To examine whether cell death was due to induction of cas-
pase-dependent programmed cell death, the activation of the
caspases that drive the eﬀector phase of apoptosis by cleaving
key proteins was assessed. MCF-7 cells are deleted of caspase-
3 and depend mainly on caspase-7 for the execution of cell
death [27]. In agreement with previous study [27], doxorubicin
did not induce activation of caspase-7 and incompletely acti-
vated PARP cleavage in siControl transfected cells after 24 h
(Fig. 4D). However, activation of caspase-7 and cleavage of
PARP were accelerated by downregulation of SphK1 in the
presence of doxorubicin (Fig. 4D), suggesting that loss of
SphK1 enhances sensitivity to chemotherapy.4. Conclusions
EGF and downstream signaling of EGFR play important
roles in the progression, invasion, and maintenance of the
malignant phenotype of breast cancer. This work solidiﬁes
the notion that SphK1 is a critical component of EGFR signal-
ing. We have now shown that EGF stimulates SphK1 in MCF-
7 breast cancer cells and induces its translocation from the
cytosol to the PM. Activation of SphK1 plays an important
role in migration of MCF-7 cells towards EGF as downregu-
lation of its expression almost completely blocked migration.
SphK1 is also critical for cell growth stimulation not only by
EGF but also by serum and blocking its expression induced
cell cycle arrest, suggesting that SphK1 is important for
MCF-7 cell cycle progression. Finally SphK1 protects MCF7
cells from doxorubicin induced apoptosis suggesting that loss
of SphK1 should increase sensitivity to chemotherapy. To-
gether these results implicate SphK1 as a key regulator of
many processes involved in breast cancer progression, thus
making it an attractive therapeutic target.
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